Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa in Myelofibrosis with Myeloid Metaplasia
NCT00287261Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2006
- Primary completion
- Mar 2008
- Countries
- 6
01
Overview
Phase 2, open-label trial of zoledronic acid in myelofibrosis with myeloid metaplasia (MMM), sponsored by UZ Leuven. Primary endpoints: Hemoglobin level at 36 weeks and Spleen size at 36 weeks. Started Feb 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
myelofibrosis with myeloid metaplasia (MMM)
Beyond the preview
Go deeper on NCT00287261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287261.